Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc (DMAC) is a clinical-stage biopharmaceutical company advancing novel therapies for neurological disorders and chronic kidney disease. This page serves as the definitive source for DMAC-related news, providing investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access the latest press releases detailing progress on DM199 – the company's recombinant human tissue kallikrein-1 therapy – along with strategic partnerships and peer-reviewed research findings. Our curated news collection covers essential updates including trial results, FDA communications, and scientific presentations, helping stakeholders track the company's progress in addressing unmet medical needs.
Key focus areas include advancements in acute ischemic stroke treatments and chronic kidney disease management. Bookmark this page for streamlined access to earnings reports, investor conference materials, and analysis of DMAC's position within the competitive biopharmaceutical landscape. All content is maintained to reflect the most current and relevant information for informed decision-making.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has completed a $30.1 million private placement by selling approximately 8.6 million common shares at $3.50 per share. After expenses, the company received net proceeds of $29.9 million.
The company's pro forma cash position, including the placement proceeds, would have been $67.2 million as of March 31, 2025, up from $37.3 million. Notably, significant participation came from related parties, with $16.8 million invested by non-management related parties. Major investors included Thomas von Koch (increasing stake to 16.2%), Trill AB (increasing to 13.1%), and Richard Jacinto II (position adjusting to 9.6%).
DiaMedica Therapeutics (Nasdaq: DMAC) has secured a $30.1 million private placement of common shares at $3.50 per share, with participation from current investors. The company will issue 8,606,426 common shares, with the transaction expected to close around July 23, 2025.
The funding will support DiaMedica's operations for over two years, focusing on their clinical program for preeclampsia and fetal growth restriction treatments. Key milestones include submitting an IND application in the United States and conducting a Phase 2b study to evaluate DM199 in both indications, pending approval.
The private placement qualifies as a related party transaction under Canadian securities regulations but is exempt from valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
DiaMedica Therapeutics (Nasdaq: DMAC) announced positive interim Phase 2 results for DM199 (rinvecalinase alfa) in treating preeclampsia. The study demonstrated statistically significant blood pressure reductions, with the highest dose cohort showing decreases of -35 mmHg in systolic and -15 mmHg in diastolic blood pressure (p<0.05).
Key findings include no placental transfer of DM199 and a 13.2% reduction in uterine artery pulsatility index (p=0.0003), suggesting improved placental blood flow. The treatment was generally safe with only mild adverse events reported. The study enrolled patients with mean baseline systolic/diastolic blood pressure of 165/102 mmHg at 37 weeks gestation.
The company will proceed with the dose expansion cohort (Part 1b) and initiate enrollment in the fetal growth restriction cohort (Part 3), potentially offering the first pharmacological treatment for preeclampsia in the US and Europe.
DiaMedica Therapeutics (NASDAQ:DMAC), a clinical-stage biopharmaceutical company, announced its upcoming inclusion in the Russell 2000® and Russell 3000® Indexes, effective after market close on June 27, 2025. This milestone enhances the company's visibility among institutional investors, as these indexes are widely used as benchmarks for investment strategies.
The company recently hosted a preeclampsia webinar featuring key opinion leaders discussing their lead candidate DM199, the first pharmaceutically active recombinant form of the KLK1 protein. DiaMedica expects to announce Phase 2 top-line results by mid-July for their preeclampsia treatment program.
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing treatments for preeclampsia and acute ischemic stroke, has announced its participation in the Jefferies Global Healthcare Conference. The event will take place in New York City from June 3-5, 2025. President and CEO Rick Pauls and Chief Business Officer Dave Wambeke will deliver a presentation on June 4, 2025, at 12:50 PM Eastern Time. The management team will also be available for one-on-one meetings with investors to discuss the company's strategy, recent developments, and future outlook.
DiaMedica Therapeutics (NASDAQ: DMAC) announced a virtual Key Opinion Leader (KOL) event scheduled for May 28, 2025, at 8:00 AM ET. The webinar will feature prominent experts including Prof. Stephen Tong, Prof. Susan Walker, and Prof. Baha Sibai, who will discuss preeclampsia treatment landscape and the design of DM199's Phase 2 clinical trial.
The event will focus on DM199 (Rinvecalinase Alfa), the company's novel treatment for preeclampsia, a life-threatening pregnancy-associated vascular disorder with no approved therapeutics. DM199 works by enhancing the body's natural ability to produce nitric oxide, prostacyclin, and endothelium-derived hyper polarizing factor, potentially lowering blood pressure, improving endothelial health, and enhancing perfusion to maternal organs and placenta.
DiaMedica Therapeutics (NASDAQ: DMAC) announced a poster presentation at the 11th European Stroke Organisation Conference (ESOC 2025) in Helsinki, Finland from May 21-23, 2025. The poster (P-704) will present safety and clinical outcomes data from the ReMEDy2 study, a pivotal phase 2/3 trial of DM199 (rinvecalinase alfa) in acute ischemic stroke patients.
Dr. John J. Volpi, a ReMEDy2 trial Scientific Advisory Board Member, will be available on May 22, 2025, to answer questions about the poster titled "Assessing Safety and Clinical Outcomes of Rinvecalinase Alfa (DM199) in Acute Ischemic Stroke Patients Pre-treated with Intravenous Thrombolytics Only." The company will also exhibit at booth D4.1.
DiaMedica Therapeutics (NASDAQ: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in three major investor conferences in May 2025. The company will attend the RBC Capital Markets Global Healthcare Conference (May 20-21) and the H.C. Wainwright BioConnect Conference (May 20) in New York City, where management will conduct a fireside chat at 3:30 PM ET. Additionally, DiaMedica will participate in the Craig-Hallum Institutional Investor Conference in Minneapolis on May 28.
DiaMedica's primary focus is developing novel treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein, targeting conditions such as preeclampsia and acute ischemic stroke.
DiaMedica Therapeutics (NASDAQ: DMAC) has announced it will release its first quarter 2025 financial results after market close on Tuesday, May 13th, followed by a conference call on Wednesday, May 14th at 7:00 AM CT. The company, which focuses on developing treatments for preeclampsia and acute ischemic stroke, will provide a business update during the call.
The conference call will be accessible via webcast at https://app.webinar.net/24NpV0mjklG or by dialing (800) 836-8184 with Conference ID 93262. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant form of the KLK1 protein, which has established therapeutic applications in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.
FAQ
What is the current stock price of Diamedica Therapeutics (DMAC)?
What is the market cap of Diamedica Therapeutics (DMAC)?
